Specialty Enzymes Market

The global specialty enzymes market is projected to reach USD 9.2 Billion by 2029, growing at a CAGR of 8.5% from 2024 to 2029. The global demand for specialty enzymes in pharmaceuticals, diagnostics, research, and biotechnology is growing due to several factors. Advancements in biotechnology and medical research are driving the need for more precise and efficient enzymes for drug development and disease diagnosis. The increasing prevalence of chronic diseases and the aging population are spurring demand for innovative diagnostic tools and personalized medicine. Additionally, advancements in enzyme engineering are enhancing enzyme specificity and stability, expanding their applications. The rise of biopharmaceuticals and the expanding use of enzymes in genetic engineering, clinical diagnostics, and industrial processes further fuel this demand, highlighting their critical role in modern healthcare and research. The players in the market are actively involved in collaborations for specialty enzymes. In November 2021, Novozymes A/S (Denmark) and Novo Nordisk Pharmatech (Denmark) collaborated in  in developing specialty enzymes for the biopharmaceutical industry, particularly regenerative medicines. This collaboration is poised to enhance Novozymes A/S’s position in the pharmaceutical enzyme market. By leveraging their joint competencies and resources, the companies aim to address the growing demand for high-quality enzymatic processing aids in the production of proteins and cells, especially for stem cell and gene therapies. This strategic partnership enables Novozymes A/S to expand its product offerings and tap into emerging opportunities in the biopharmaceutical sector, strengthening its presence in the pharmaceutical enzyme market.

The key players in the specialty enzymes market are Brain Biotech AG (Germany), Novozymes A/S (Denmark), Codexis, Inc. (US), Sanofi (France), Merck KGaA (Germany) among others. The key strategies the leading market players adopt include product launches, collaborations, partnerships, and expansion to increase their market share. For instance, in December 2021 Codexis, Inc. (US) launched the Codex HiTemp Reverse Transcriptase. This enzyme is specifically engineered and optimized for enhanced thermostability and robustness to address known challenges in handling clinical samples. This novel innovation will help Codexis to establish its name in the pharmaceutical enzyme market. In April 2020 BRAIN Biotech AG (Germany), expanded its Cardiff production facilities with a 10,000-liter fermenter, significantly increasing its enzyme production capacity. This state-of-the-art facility, designed for lean manufacturing, enhances efficiency and resource use. By scaling up to tonne-level production, Biocatalysts can better serve the life sciences, and pharmaceutical industries, solidifying its position in the specialty enzyme market.

To know about the assumptions considered for the study download the pdf brochure

Brain Biotech AG is a leading industrial biotechnology specialist, renowned for developing and producing enzymes, proteins, microbial production strains, and bioactive natural products tailored for industrial applications. With a strong emphasis on sustainability, their innovative bio-based solutions enhance the efficiency and environmental footprint of industrial processes. The company's operations are categorized into three business segments: BioProducts, BioScience, and BioIncubator. The BioProducts segment, which includes the enzyme business, focuses on the production and commercialization of enzymes and other proteins. The company has involved in launching High-performance production strains for enzymes. In November 2023, BRAIN Biotech AG's (Germany) interdisciplinary project teams, comprising experts in microbiology, molecular biology, and bioprocess development, optimized an Aspergillus Niger strain for efficient enzyme and alternative protein production, achieving yields in the double-digit gram-per-liter range. This innovation positions BRAIN Biotech AG to significantly advance in the specialty enzyme market by replacing a large proportion of animal proteins with sequence-identical, microbially produced proteins, enhancing sustainability and efficiency.

Codexis, Inc. (US) is a leading enzyme engineering company utilizing its proprietary CodeEvolver technology platform to discover, develop, and enhance high-performance enzymes and proteins. Its enzymes address challenges in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. The company is developing its ECO Synthesis platform for scalable RNAi therapeutics production. Codexis’ enzymes offer higher yields, reduced energy use, waste reduction, and improved manufacturing efficiency. Codexis, Inc. is involved in several partnership and collaboration with other companies worldwide.  In July 2022, Codexis, Inc. (US)  agreed with Pfizer (Japan) to supply a proprietary high-performance enzyme used to manufacture an active pharmaceutical ingredient (API) in PAXLOVID. This agreement will help both companies’ presence worldwide in the enzyme market. In April 2022, Codexis, Inc. (US) and Molecular Assemblies (US) collaborated to develop high-performing enzymes to enable the fully enzymatic synthesis of DNA. This collaboration will help Codexis to enhance its product portfolio and market reach.

Related Reports:

Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Proteases, Lipases, Polymerases & Nucleases), Application (Pharmaceuticals, Diagnostics, Research & Biotechnology), Form & Region - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]